Development programme
REDEFINE — cagrilintide with semaglutide
The phase 3 programme for the fixed-combination of the long-acting amylin analogue cagrilintide with semaglutide.
The phase 3 programme for the fixed-combination of the long-acting amylin analogue cagrilintide with semaglutide.
Sponsor class: Manufacturer-sponsored. First record: 2022.
Showing 0 records on this page
Records in this programme
12 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| REDEFINE-1 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 3,417 | 2025 | Moderate |
| REDEFINE-2 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,206 | 2025 | Moderate |
| REDEFINE-4 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| REDEFINE-1-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-1-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-2-BIOMARKERprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-OLEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| REDEFINE-4-DDIprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 1 | Ongoing | Randomised crossover | — | — | Very low |
| REDEFINE-4-PKprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| REDEFINE-4-RENAL-IMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |